Trial Profile
A Randomized Comparison of Platelet Inhibition Using a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-6 Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2021
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Clopidogrel
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Acronyms OPTIMUS-6
- 15 Jan 2021 Status changed from active, no longer recruiting to completed.
- 11 Dec 2020 Planned End Date changed from 1 Aug 2020 to 1 Dec 2020.
- 13 Oct 2020 Results published in the Circulation